209 related articles for article (PubMed ID: 36781850)
41. Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia.
Ferrari A; Ghelli Luserna Di Rora A; Domizio C; Papayannidis C; Simonetti G; Maria Hernández-Rivas J; Rondoni M; Giglio F; Abruzzese E; Imovilli A; Iacobucci I; Calistri D; Martinelli G
Br J Haematol; 2021 Mar; 192(6):e139-e144. PubMed ID: 33314053
[No Abstract] [Full Text] [Related]
42. Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements.
De Lorenzo P; Moorman AV; Pieters R; Dreyer ZE; Heerema NA; Carroll AJ; Hunger SP; Harvey R; Willman CL; Devidas M; Valsecchi MG; Harrison CJ
Leukemia; 2014 Feb; 28(2):428-30. PubMed ID: 24072099
[No Abstract] [Full Text] [Related]
43. Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
Tsaur G; Popov A; Riger T; Kustanovich A; Solodovnikov A; Shorikov E; Demina A; Verzhbitskaya T; Streneva O; Makarova O; Lapotentova E; Aleinikova O; Miakova N; Boichenko E; Kondratchik K; Ponomareva N; Karachunskiy A; Roumiantsev A; Fechina L
Br J Haematol; 2021 Jun; 193(6):1151-1156. PubMed ID: 33583020
[TBL] [Abstract][Full Text] [Related]
44. Case Report: Rare
Eadie LN; Rehn JA; Breen J; Osborn MP; Jessop S; Downes CEJ; Heatley SL; McClure BJ; Yeung DT; Revesz T; Saxon B; White DL
Genes (Basel); 2023 Jan; 14(2):. PubMed ID: 36833191
[TBL] [Abstract][Full Text] [Related]
45. Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.
Loftus JP; Yahiaoui A; Brown PA; Niswander LM; Bagashev A; Wang M; Schauf A; Tannheimer S; Tasian SK
Haematologica; 2021 Apr; 106(4):1067-1078. PubMed ID: 32414848
[TBL] [Abstract][Full Text] [Related]
46. Genetic and Epigenetic Characterization of a Discordant
Russo A; Viberti C; Mareschi K; Casalone E; Guarrera S; Birolo G; Cazzaniga G; Corral L; Trentin L; Basso G; Fagioli F; Matullo G
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575904
[TBL] [Abstract][Full Text] [Related]
47. [Treatment strategy for infant acute lymphoblastic leukemia].
Miyamura T
Rinsho Ketsueki; 2022; 63(7):791-798. PubMed ID: 35922950
[TBL] [Abstract][Full Text] [Related]
48. Therapy-related myeloid neoplasm in an 18-year-old boy with B-lymphoblastic leukemia.
Qing X; Panosyan E; Yue C; Ji P; Gotesman M; French S; Cai J
Exp Mol Pathol; 2017 Dec; 103(3):263-266. PubMed ID: 29155023
[TBL] [Abstract][Full Text] [Related]
49. Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis.
Agraz-Doblas A; Bueno C; Bashford-Rogers R; Roy A; Schneider P; Bardini M; Ballerini P; Cazzaniga G; Moreno T; Revilla C; Gut M; Valsecchi MG; Roberts I; Pieters R; De Lorenzo P; Varela I; Menendez P; Stam RW
Haematologica; 2019 Jun; 104(6):1176-1188. PubMed ID: 30679323
[TBL] [Abstract][Full Text] [Related]
50. Acute myeloid leukemia with t(10;11)(p11-12;q23.3): Results of Russian Pediatric AML registration study.
Zerkalenkova E; Lebedeva S; Kazakova A; Tsaur G; Starichkova Y; Timofeeva N; Soldatkina O; Aprelova E; Popov A; Ponomareva N; Baidun L; Meyer C; Novichkova G; Maschan M; Maschan A; Marschalek R; Olshanskaya Y
Int J Lab Hematol; 2019 Apr; 41(2):287-292. PubMed ID: 30624859
[TBL] [Abstract][Full Text] [Related]
51. Outstanding outcomes in infants with
Guest EM; Kairalla JA; Hilden JM; Dreyer ZE; Carroll AJ; Heerema NA; Wang CY; Devidas M; Gore L; Salzer WL; Winick NJ; Carroll WL; Raetz EA; Borowitz M; Loh ML; Hunger SP; Brown PA
Haematologica; 2022 May; 107(5):1205-1208. PubMed ID: 35172563
[No Abstract] [Full Text] [Related]
52. Rare
Panagopoulos I; Andersen K; Eilert-Olsen M; Rognlien AG; Munthe-Kaas MC; Micci F; Heim S
Cancer Genomics Proteomics; 2021; 18(2):121-131. PubMed ID: 33608309
[TBL] [Abstract][Full Text] [Related]
53. Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia.
Isobe T; Takagi M; Sato-Otsubo A; Nishimura A; Nagae G; Yamagishi C; Tamura M; Tanaka Y; Asada S; Takeda R; Tsuchiya A; Wang X; Yoshida K; Nannya Y; Ueno H; Akazawa R; Kato I; Mikami T; Watanabe K; Sekiguchi M; Seki M; Kimura S; Hiwatari M; Kato M; Fukuda S; Tatsuno K; Tsutsumi S; Kanai A; Inaba T; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Kotecha RS; Cruickshank MN; Ishikawa F; Morio T; Eguchi M; Deguchi T; Kiyokawa N; Arakawa Y; Koh K; Aoki Y; Ishihara T; Tomizawa D; Miyamura T; Ishii E; Mizutani S; Wilson NK; Göttgens B; Miyano S; Kitamura T; Goyama S; Yokoyama A; Aburatani H; Ogawa S; Takita J
Nat Commun; 2022 Aug; 13(1):4501. PubMed ID: 36042201
[TBL] [Abstract][Full Text] [Related]
54. High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Lee JW; Kim Y; Cho B; Kim S; Jang PS; Lee J; Cho H; Lee GD; Chung NG; Kim M
Cancer Med; 2020 Jul; 9(13):4632-4639. PubMed ID: 32378810
[TBL] [Abstract][Full Text] [Related]
55. A novel regimen for relapsed/refractory adult acute myeloid leukemia using a
Mims AS; Mishra A; Orwick S; Blachly J; Klisovic RB; Garzon R; Walker AR; Devine SM; Walsh KJ; Vasu S; Whitman S; Marcucci G; Jones D; Heerema NA; Lozanski G; Caligiuri MA; Bloomfield CD; Byrd JC; Piekarz R; Grever MR; Blum W
Haematologica; 2018 Jun; 103(6):982-987. PubMed ID: 29567781
[No Abstract] [Full Text] [Related]
56. Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols.
Motlló C; Ribera JM; Morgades M; Granada I; Montesinos P; Brunet S; Bergua J; Tormo M; García-Boyero R; Sarrà J; Del Potro E; Grande C; Barba P; Bernal T; Amigo ML; Grau J; Cervera J; Feliu E;
Leuk Lymphoma; 2017 Jan; 58(1):145-152. PubMed ID: 27122129
[TBL] [Abstract][Full Text] [Related]
57. The EGR3 regulome of infant KMT2A-r acute lymphoblastic leukemia identifies differential expression of B-lineage genes predictive for outcome.
Külp M; Larghero P; Alten J; Cario G; Eckert C; Caye-Eude A; Cavé H; Schmachtel T; Bardini M; Cazzaniga G; De Lorenzo P; Valsecchi MG; Bonig H; Meyer C; Rieger MA; Marschalek R
Leukemia; 2023 Jun; 37(6):1216-1233. PubMed ID: 37100882
[TBL] [Abstract][Full Text] [Related]
58. Differential network analysis and protein-protein interaction study reveals active protein modules in glucocorticoid resistance for infant acute lymphoblastic leukemia.
Mousavian Z; Nowzari-Dalini A; Rahmatallah Y; Masoudi-Nejad A
Mol Med; 2019 Aug; 25(1):36. PubMed ID: 31370801
[TBL] [Abstract][Full Text] [Related]
59. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation.
Nguyen D; Kantarjian HM; Short NJ; Qiao W; Ning J; Cuglievan B; Daver NG; DiNardo CD; Jabbour EJ; Kadia TM; Borthakur G; Garcia-Manero G; Konopleva MY; Andreeff M; Ravandi-Kashani F; Sasaki K; Issa GC
Cancer; 2023 Jun; 129(12):1856-1865. PubMed ID: 36892949
[TBL] [Abstract][Full Text] [Related]
60. MLL gene in maternal and infantile acute lymphoblastic leukemia and the effect of estrogen.
Aljurf M; Saleh AJ; Ahmed SO
Leuk Res; 2011 Jul; 35(7):e127. PubMed ID: 21396712
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
